Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Maria Gonzalez-Cao"'
Autor:
Rafael Rosell, Maria Gonzalez-Cao
Publikováno v:
The Lancet. 397:557-559
Autor:
Silvia Muñoz, William P.J. Leenders, A. Aguilar-Hernández, Luis M. Montuenga, Roxana Reyes, Maria Gonzalez-Cao, R. Roman, Elena Gonzalvo, Cristina Sainz, Cristina Teixidó, Andrés F. Cardona, Maria D. Lozano, Elba Marin, Ainara Arcocha, Carlos R. Cabrera, Miguel Mesa-Guzman, Aleix Prat, Miguel Angel Molina-Vila, I. Sullivan, Cristina Aguado, Alejandro Martinez-Bueno, Erika Aldeguer, Irene Moya, Ramon Palmero, Noemi Reguart, Rafael Rosell, Laura López-Vilaró, Ana Giménez-Capitán, Santiago Viteri, Sonia Rodríguez, Sergi Castillo, Nuria Viñolas
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Fundacion Sancho el Sabio Fundazioa (FSS)
Molecular Oncology, Vol 15, Iss 2, Pp 350-363 (2021)
Molecular Oncology, 15, 350-363
Scientia
Molecular Oncology, 15, 2, pp. 350-363
Universitat Autònoma de Barcelona
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Fundacion Sancho el Sabio Fundazioa (FSS)
Molecular Oncology, Vol 15, Iss 2, Pp 350-363 (2021)
Molecular Oncology, 15, 350-363
Scientia
Molecular Oncology, 15, 2, pp. 350-363
We studied MET alterations in 474 advanced non‐small‐cell lung cancer (NSCLC) patients by nCounter, an RNA‐based technique. We identified 3% with METΔex14 mRNA and 3.5% with very‐high MET mRNA expression, a surrogate of MET amplification. ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c00b42c81cc41a7f2eb1ec563f3b10
https://ddd.uab.cat/record/238801
https://ddd.uab.cat/record/238801
Autor:
Maria Gonzalez Cao, Elisa Giovannetti, Alessandro D'Aveni, Maria Grazia Daffinà, Niki Karachaliou, Alessia Liguori, Rafael Rosell, Giuseppe Altavilla, Mariacarmela Santarpia, Grazia Marabello
Publikováno v:
Drug design, development and therapy 11 (2017): 2047–2063. doi:10.2147/DDDT.S113500
info:cnr-pdr/source/autori:Santarpia M.; Daffina M.G.; D'Aveni A.; Marabello G.; Liguori A.; Giovannetti E.; Karachaliou N.; Cao M.G.; Rosell R.; Altavilla G./titolo:Spotlight on ceritinib in the treatment of ALK+ NSCLC: Design, development and place in therapy/doi:10.2147%2FDDDT.S113500/rivista:Drug design, development and therapy/anno:2017/pagina_da:2047/pagina_a:2063/intervallo_pagine:2047–2063/volume:11
Drug Design, Development and Therapy, Vol Volume 11, Pp 2047-2063 (2017)
Santarpia, M, Daffinà, M G, D’Aveni, A, Marabello, G, Liguori, A, Giovannetti, E, Karachaliou, N, Cao, M G, Rosell, R & Altavilla, G 2017, ' Spotlight on ceritinib in the treatment of ALK+ NSCLC : Design, development and place in therapy ', Drug Design, Development and Therapy, vol. 11, pp. 2047-2063 . https://doi.org/10.2147/DDDT.S113500
Drug Design, Development and Therapy
info:cnr-pdr/source/autori:Santarpia M.; Daffina M.G.; D'Aveni A.; Marabello G.; Liguori A.; Giovannetti E.; Karachaliou N.; Cao M.G.; Rosell R.; Altavilla G./titolo:Spotlight on ceritinib in the treatment of ALK+ NSCLC: Design, development and place in therapy/doi:10.2147%2FDDDT.S113500/rivista:Drug design, development and therapy/anno:2017/pagina_da:2047/pagina_a:2063/intervallo_pagine:2047–2063/volume:11
Drug Design, Development and Therapy, Vol Volume 11, Pp 2047-2063 (2017)
Santarpia, M, Daffinà, M G, D’Aveni, A, Marabello, G, Liguori, A, Giovannetti, E, Karachaliou, N, Cao, M G, Rosell, R & Altavilla, G 2017, ' Spotlight on ceritinib in the treatment of ALK+ NSCLC : Design, development and place in therapy ', Drug Design, Development and Therapy, vol. 11, pp. 2047-2063 . https://doi.org/10.2147/DDDT.S113500
Drug Design, Development and Therapy
Mariacarmela Santarpia,1 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Alessia Liguori,1 Elisa Giovannetti,2–4 Niki Karachaliou,5 Maria Gonzalez Cao,6 Rafael Rosell,7,8 Giuseppe Altavilla1 1Medical Oncology Unit, Department of H
Autor:
Aaron E. Sosa, Mariacarmela Santarpia, Jordi Berenguer, Niki Karachaliou, Rafael Rosell, Giuseppe Altavilla, Cristina Teixidó, Maria Gonzalez Cao, Alejandra Rodriguez Capote
Publikováno v:
Expert Opinion on Investigational Drugs
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The
Autor:
Danilo Rocco, Niki Karachaliou, Clara Mayo de-las-Casas, Alejandro Martinez-Bueno, Roberta Sgariglia, Pasquale Pisapia, Umberto Malapelle, Claudio Bellevicine, Francesco Pepe, Rafael Rosell, Caterina De Luca, Miguel Angel Molina-Vila, Daniela Morales-Espinosa, Giancarlo Troncone, Mónica Garzón, Maria Giovanna Russo, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Núria Jordana-Ariza
Publikováno v:
British Journal of Cancer
Background: When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relev
Autor:
Giancarlo Troncone, Umberto Malapelle, Santiago Viteri-Ramirez, Clara Mayo-de-las-Casas, Noemí Reguart, Niki Karachaliou, Ariadna Balada-Bel, Maria José Catalán, Ana Blasco, Beatriz García-Peláez, Alejandro Martinez-Bueno, Núria Jordana-Ariza, Mónica Garzón-Ibáñez, Rafael Rosell, Raquel Campos, Sergio Villatoro, Miguel Angel Molina-Vila, Irene Moya-Horno, R. Blanco, Maria Gonzalez-Cao, Margarita Majem, Xavier Gonzalez
Publikováno v:
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74031d25b8b6b6755deee5fc272706e0
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2889
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2889
Publikováno v:
Expert Review of Clinical Pharmacology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: Different EGFR tyrosine kinase inhibitors (TKIs) are currently approved for the first-line treatment of NSCLC patients with EGFR mutations. Dacomitinib is an orally administered, second-generation pan-HER inhibitor that has shown to imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680f6325f58715fa95bc8a398df7c862
http://hdl.handle.net/11577/3305476
http://hdl.handle.net/11577/3305476
Autor:
Juan José García-Mosquera, Andrés Aguilar, Santiago Viteri, Niki Karachaliou, Rafael Rosell, Maria Gonzalez-Cao
Publikováno v:
Cancer Cell
Summary Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3236406b4150faea389ef8468e7c55a7
https://europepmc.org/articles/PMC6328696/
https://europepmc.org/articles/PMC6328696/
Autor:
Maria Gonzalez-Cao, Elisa Giovannetti, Niki Karachaliou, Mariacarmela Santarpia, Giuseppe Altavilla, Rafael Rosell
Publikováno v:
Santarpia, M, Karachaliou, N, González-Cao, M, Altavilla, G, Giovannetti, E & Rosell, R 2016, ' Feasibility of cell-free circulating tumor DNA testing for lung cancer ', Biomarkers in medicine, vol. 10, no. 4, pp. 417-30 . https://doi.org/10.2217/bmm.16.6
Biomarkers in medicine, 10(4), 417-30. Future Medicine Ltd.
Biomarkers in medicine, 10(4), 417-30. Future Medicine Ltd.
Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing,
Autor:
Mar Varela, Jean-François Emile, Marie Brevet, Jose Carlos Ruffinelli, Noelia Vilariño, Marta Gut, Rafael Rosell, Amparo Benito, Pilar Garrido, Maria Gonzalez-Cao, Sergio Peralta, Sebastian Moran, Nicolas Girard, Lidia Perez, Elisabeth Brambilla, David Piñeyro, Marie-Christine Copin, Enrica Capelletto, Luis M. Montuenga, Niki Karachaliou, Isabel Barragan, Immaculada Ramos, Monica Pradotto, Teresa Moran, Noemi Reguart, Mario F. Fraga, Coraline Dumenil, Aleix Prat, Alexis B. Cortot, Paolo Bironzo, Ignacio Gil-Bazo, Qingyang Xiao, Ramon Palmero, Agustín F. Fernández, Cristina Teixidó, Manuel Castro de Moura, Veronica Davalos, Ernest Nadal, Michael Duruisseaux, Iosune Baraibar, Montse Sanchez-Cespedes, Maria D. Lozano, Maria E. Calleja-Cervantes, Manel Esteller, Anna Martínez-Cardús, Ivo Gut, Etienne Giroux-Leprieur, Silvia Novello
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
Recercat. Dipósit de la Recerca de Catalunya
The Lancet Respiratory Medicine
LANCET RESPIRATORY MEDICINE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Universidad de Barcelona
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
Recercat. Dipósit de la Recerca de Catalunya
The Lancet Respiratory Medicine
LANCET RESPIRATORY MEDICINE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8510d954d8d5639ed603903adf535b35
http://hdl.handle.net/2445/125743
http://hdl.handle.net/2445/125743